Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

48.31 +0.46 (+0.96%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
36 37 Next >
(SNY) - Analyzing Sanofi's Short Interest
Via Benzinga
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising. 
Via InvestorPlace
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year. 
Via Benzinga
3 Cash Cow Dividend Stocks for Outsized Income & Upside
With uncertainty again weighing on the market, investors can take shelter under these cash cow dividend stocks. 
Via InvestorPlace
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons why 
Via MarketBeat
Topics Lawsuit
Why the dividend investor may take a look at NASDAQ:SNY.
Exploring SANOFI-ADR (NASDAQ:SNY)'s dividend characteristics. 
Via Chartmill
NASDAQ:SNY is an undervalued gem with solid fundamentals.
SANOFI-ADR (NASDAQ:SNY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Move Over Magnificent 7, Say Hello to the GRANOLAS
Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods. 
Via InvestorPlace
Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests
The FDA put studies in eczema and asthma treatment on clinical hold. 
Via Investor's Business Daily
Cruising For A Bruising
We’re currently living in the soft landing, and it is pleasant indeed. But inflation numbers at the start of the year have put us on notice. Like the Magnificent Seven, hopes of a sustained soft... 
Via Talk Markets
Topics Economy
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
Don't count these companies out too soon. 
Via The Motley Fool
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts. 
Via InvestorPlace
Sanofi's Earnings Outlook
Via Benzinga
Analyzing NASDAQ:SNY's Dividend Potential.
Balancing Dividends and Fundamentals: The Case of SANOFI-ADR (NASDAQ:SNY). 
Via Chartmill
The 3 Biotech Stocks That Could Make Your February Unforgettable
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks. 
Via InvestorPlace
What's Going On Eli Lilly Stock Thursday?
Eli Lilly's impressive stock surge, better-than-expected Q4 results, and positive analyst reviews. 
Via Benzinga
Novo Nordisk To Up Production Capacity As Parent Buys Catalent
NVO stock rose after Novo Nordisk's parent, Novo Holdings, said it has agreed to buy contract manufacturer Catalent for $11.5 billion in cash. 
Via Investor's Business Daily
CytoReason's AI-Driven Disease Model Platform Trusted By 5 Top 10 Pharma Companies Harnesses Big Data To Speed Drug Discovery And Development
Click here to learn more about CytoReason and how to invest through OurCrowd.  
Via Benzinga
Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets
Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones. 
Via Talk Markets
Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today?
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77. 
Via Benzinga
Sanofi (SNY) Q4 2023 Earnings Call Transcript
SNY earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results. 
Via Benzinga
French Pharma Giant Sanofi's Q4 Earnings Hit By Aubagio Generic Competition, Helped By Flagship Eczema And Newly Launched Hemophilia Drugs
Sanofi reports Q4 operating income of €2.6B, down 5.2%. Revenues rise 1.8% to €10.92B, Specialty Care grows 13.7%, Dupixent sales surge. 
Via Benzinga
Sanofi's Biggest Drug Shined. But The Rest Of Its Business Didn't.
The company missed total sales and earnings expectations. 
Via Investor's Business Daily
Nasdaq Futures Rebound As Traders Eye Apple, Meta, Amazon Earnings: Analyst Flags 'January Barometer' That Bodes Well For The Year
After ending January with modest gains, the major averages now look to earnings catalysts to drive momentum, with futures higher in first trading session of February. 
Via Benzinga
MaxLinear Reports Q4 Results, Joins ING, Wolfspeed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 90 points on Thursday. 
Via Benzinga
Earnings Scheduled For February 1, 2024
Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NYSE:SHEL) is likely to report quarterly earnings at $1.81 per share on... 
Via Benzinga
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending. 
Via Benzinga
Topics Artificial Intelligence
Regeneron/Sanofi's Largest Selling Drug Dupixent Scores FDA Approval For Infants With Esophagus Inflammation
FDA approves Dupixent (dupilumab) by Regeneron/Sanofi for pediatric eosinophilic esophagitis treatment. Breakthrough treatment for young patients. 
Via Benzinga
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.